HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2011 | 784 | 923 | 84.9% | |
| HF 4 | 2012 | 835 | 964 | 86.6% | |
| HF 4 | 2013 | 910 | 1031 | 88.3% | |
| HF004 | 2014 | 787 | 864 | 91.1% | |
| HF004 | 2015 | 853 | 926 | 92.1% | |
| HF004 | 2016 | 881 | 961 | 91.7% | |
| HF004 | 2017 | 892 | 967 | 92.2% | |
| HF004 | 2018 | 948 | 1033 | 91.8% | |
| HF004 | 2019 | 1071 | 1188 | 90.2% | |
| HF004 | 2020 | 1194 | 1323 | 90.2% |
